Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin

Ann Hematol. 2021 Nov;100(11):2873-2875. doi: 10.1007/s00277-021-04633-6. Epub 2021 Aug 24.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged, 80 and over
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Brentuximab Vedotin / therapeutic use*
  • Female
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / complications
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, T-Cell, Peripheral / complications
  • Lymphoma, T-Cell, Peripheral / drug therapy*
  • Rituximab / therapeutic use*
  • T-Lymphocytes, Helper-Inducer / drug effects

Substances

  • Antineoplastic Agents, Immunological
  • Rituximab
  • Brentuximab Vedotin